Smartleaf Asset Management’s Apogee Therapeutics APGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-285
Closed -$37.8K – 3631
2026
Q2
$37.8K Hold
285
– – ﹤0.01% 1662
2026
Q1
$22.4K Buy
285
+9
+3% +$654 ﹤0.01% 1890
2025
Q4
$20.9K Buy
276
+175
+173% +$11K ﹤0.01% 2007
2025
Q3
$4.02K Buy
101
+22
+28% +$840 ﹤0.01% 2444
2025
Q2
$3.43K Buy
+79
New +$3K ﹤0.01% 2167
2025
Q1
– Sell
-82
Closed -$3.66K – 2869
2024
Q4
$3.66K Buy
+82
New +$4.18K ﹤0.01% 2356
2024
Q3
– Sell
-3
Closed -$119 – 2906
2024
Q2
$119 Buy
+3
New +$146 ﹤0.01% 2715

Other funds holding APGE

Smartleaf Asset Management's APGE Position: Q3 2026 in Review

Smartleaf Asset Management sold out of Apogee Therapeutics (APGE) in Q3 2026, closing a stake of 285 shares — an estimated $37.8K sold.

Smartleaf Asset Management first reported a position in APGE in Q2 2024 and held it in 7 quarters. The position peaked at $37.8K in Q2 2026. 2 funds tracked by Wall St. Rank hold APGE as of Q3 2026.

  • Smartleaf Asset Management reported no remaining Apogee Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Smartleaf Asset Management sold 285 Apogee Therapeutics shares in Q3 2026, an estimated $37.8K.
  • Smartleaf Asset Management first reported a position in Apogee Therapeutics in Q2 2024 and held it in 7 quarters.
  • Smartleaf Asset Management's Apogee Therapeutics position peaked at $37.8K in Q2 2026.
  • 2 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.